<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01290575</url>
  </required_header>
  <id_info>
    <org_study_id>MB122-004</org_study_id>
    <nct_id>NCT01290575</nct_id>
  </id_info>
  <brief_title>Multiple Ascending Dose Study of BMS-820132 in Patients With Type 2 Diabetes</brief_title>
  <official_title>Placebo-Controlled, Ascending Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-820132 in Subjects With Type 2 Diabetes Treated With Metformin Monotherapy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      BMS-820132 is an investigational new drug being developed by BMS for treating Type 2
      diabetes. The purpose of this study is to test the safety/tolerability (potential side
      effects) of multiple doses of the investigational new drug, as well as the amount of study
      drug in the blood and its effects on blood sugar,in subjects with type 2 diabetes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Classification: Safety, Pharmacokinetics/dynamics
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events, physical examinations, clinical laboratory determinations, electrocardiograms (ECG), and vital sign assessments.</measure>
    <time_frame>Throughout the study drug administration period (14 days)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse events, physical examinations, clinical laboratory determinations, electrocardiograms (ECG), and vital sign assessments.</measure>
    <time_frame>within 7 days after the final dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum observed plasma concentration (Cmax) of BMS-820132</measure>
    <time_frame>Day 1 and Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of maximum observed plasma concentration (Tmax) of BMS-820132</measure>
    <time_frame>Day 1 and Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough observed plasma concentration (Cmin) of BMS-820132</measure>
    <time_frame>Day 1 through Day 14 (selected days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve over one dosing interval [AUC(TAU)] of BMS-820132</measure>
    <time_frame>Day 1 and Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation index (AI) of BMS-820132</measure>
    <time_frame>Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half life (T-Half) of BMS-820132</measure>
    <time_frame>Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(0-24 h) and postprandial AUC(0-4h) for biomarkers of glucose homeostasis</measure>
    <time_frame>Day -1, Day 1, Day 7 and Day 14</time_frame>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Actual">67</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Arm 1 BMS-820132 or placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2 BMS-820132 or placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3 BMS-820132 or placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 4 BMS-820132 or placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 5 BMS-820132 or placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 6 BMS-820132 or placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 7 BMS-820132 or placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 8 BMS-820132 or placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 9 BMS-820132 or placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>capsule, Oral, 0.0mg, twice daily, 14 day</description>
    <arm_group_label>Arm 1 BMS-820132 or placebo</arm_group_label>
    <arm_group_label>Arm 2 BMS-820132 or placebo</arm_group_label>
    <arm_group_label>Arm 3 BMS-820132 or placebo</arm_group_label>
    <arm_group_label>Arm 4 BMS-820132 or placebo</arm_group_label>
    <arm_group_label>Arm 5 BMS-820132 or placebo</arm_group_label>
    <arm_group_label>Arm 9 BMS-820132 or placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Capsule, Oral, 0.0mg, once daily, 14 day</description>
    <arm_group_label>Arm 6 BMS-820132 or placebo</arm_group_label>
    <arm_group_label>Arm 7 BMS-820132 or placebo</arm_group_label>
    <arm_group_label>Arm 8 BMS-820132 or placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-820132</intervention_name>
    <description>Capsule, Oral, 15mg, twice daily, 14 day</description>
    <arm_group_label>Arm 1 BMS-820132 or placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-820132</intervention_name>
    <description>Capsule, Oral, 60mg, twice daily, 14 day</description>
    <arm_group_label>Arm 2 BMS-820132 or placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-820132</intervention_name>
    <description>Capsule, oral, 150mg, twice daily, 14 day</description>
    <arm_group_label>Arm 3 BMS-820132 or placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-820132</intervention_name>
    <description>Capsule, Oral, 300mg, twice daily, 14 day</description>
    <arm_group_label>Arm 4 BMS-820132 or placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-820132</intervention_name>
    <description>Capsule, Oral, 450mg, twice daily, 14 day</description>
    <arm_group_label>Arm 5 BMS-820132 or placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-820132</intervention_name>
    <description>Capsule, Oral, To be determined (TBD), once daily, 14 day</description>
    <arm_group_label>Arm 6 BMS-820132 or placebo</arm_group_label>
    <arm_group_label>Arm 7 BMS-820132 or placebo</arm_group_label>
    <arm_group_label>Arm 8 BMS-820132 or placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-820132</intervention_name>
    <description>Capsule, Oral, 5 mg, twice daily, 14 day</description>
    <arm_group_label>Arm 9 BMS-820132 or placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females of childbearing potential (willing to use an acceptable method of
             contraception), or females of non-childbearing potential (i.e., post-menopausal or
             surgically sterile).

          -  Diagnosis of type 2 diabetes treated with metformin monotherapy (at least 1500 mg/day
             for at least 6 months) on a stable regimen for at least 2 months.

          -  Body Mass Index (BMI) of 18.5 to 40 kg/m2.

          -  Fasting glucose in the range of 125-275 mg/dL.

          -  Hemoglobin A1c (HbA1c) in the range of 7.0% -11.0%.

          -  Fasting C-peptide &gt; 1 ng/mL.

        Exclusion Criteria:

          -  Clinically significant deviation from normal in medical history, physical examination,
             electrocardiograms (ECGs), and clinical laboratory determinations, and any significant
             acute or chronic medical illness other than stable and well controlled hypertension,
             microalbuminuria, dyslipidemia, depression, or hypothyroidism.

          -  History of diabetic ketoacidosis, hyperosmolar nonketotic syndrome, lactic acidosis,
             hypoglycemia (i.e., ≥ 1 self-reported episodes of hypoglycemia within the last 3
             months or ≥ 2 self-reported episodes of hypoglycemia within the last 6 months), or
             hypoglycemia unawareness.

          -  Any major surgery within 4 weeks of study drug administration.

          -  Any gastrointestinal surgery that could impact upon the absorption of study drug.

          -  Smoking more than 10 cigarettes per day.

          -  Recent drug or alcohol abuse.

          -  Women who are pregnant or breastfeeding.

          -  Positive urine screen for drugs of abuse.

          -  Positive blood screen for hepatitis C antibody, hepatitis B surface antigen, or Human
             Immunodeficiency Virus (HIV)-1, -2 antibody.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dedicated Phase I, Inc.</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osborne Research Center</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Pharmacology Of Miami Inc.</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mra Clinical Research</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cetero Research</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx</url>
    <description>Investigator Inquiry form</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>For FDA Safety Alerts and Recalls refer to the following link: http://www.fda.gov/MEDWATCH/safety.htm</description>
  </link>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 2, 2011</study_first_submitted>
  <study_first_submitted_qc>February 4, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 7, 2011</study_first_posted>
  <last_update_submitted>March 26, 2012</last_update_submitted>
  <last_update_submitted_qc>March 26, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 27, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

